Literature DB >> 8104906

Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma.

J S Castresana1, M P Rubio, J J Vázquez, M Idoate, A J Sober, B R Seizinger, R L Barnhill.   

Abstract

To investigate the role of the p53 tumor-suppressor gene in the development of human melanoma, loss of heterozygosity (LOH) of p53 was studied in 46 cases of melanoma by a polymerase-chain-reaction/restriction-fragment-length polymorphism (PCR/RFLP) analysis, and p53 mutations were assessed in 51 cases of melanoma by a polymerase-chain-reaction/single-strand-conformation polymorphism (PCR/SSCP) analysis. Frozen tumors and paraffin samples were used in the study. We were not able to detect any allelic loss in 12BstUI informative cases or any single mutation in exons 5 to 8 of the p53 gene. Our results, together with other findings at the DNA level, suggest that the p53 gene appears not to be commonly involved in the development of melanoma, at least by its most frequent mechanisms of deletion of one allele and/or mutation in the other.

Entities:  

Mesh:

Year:  1993        PMID: 8104906     DOI: 10.1002/ijc.2910550407

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

1.  Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide.

Authors:  A G Ostermeyer; E Runko; B Winkfield; B Ahn; U M Moll
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

2.  Dual inactivation of RB and p53 pathways in RAS-induced melanomas.

Authors:  N Bardeesy; B C Bastian; A Hezel; D Pinkel; R A DePinho; L Chin
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

Review 3.  Melanoma genetics and the development of rational therapeutics.

Authors:  Yakov Chudnovsky; Paul A Khavari; Amy E Adams
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

4.  Genetic alterations in quadruple malignancies of a patient with multiple sclerosis: their role in malignancy development and response to therapy.

Authors:  Zorica Milosevic; Nikola Tanic; Jasna Bankovic; Tijana Stankovic; Marko Buta; Dragana Lavrnic; Zorka Milovanovic; Gordana Pupic; Sonja Stojkovic; Vedrana Milinkovic; Yasuhiro Ito; Radan Dzodic
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

Review 5.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

6.  Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.

Authors:  V K Goel; N Ibrahim; G Jiang; M Singhal; S Fee; T Flotte; S Westmoreland; F S Haluska; P W Hinds; F G Haluska
Journal:  Oncogene       Date:  2009-04-27       Impact factor: 9.867

7.  Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions.

Authors:  T Papp; M Jafari; D Schiffmann
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

8.  Expression of the p53 protein in malignant melanomas as a prognostic indicator.

Authors:  M Yamamoto; H Takahashi; K Saitoh; T Horikoshi; M Takahashi
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

9.  Establishment and characterization of a primary and a metastatic melanoma cell line from Grey horses.

Authors:  Monika H Seltenhammer; Elisabeth Sundström; Claudia Meisslitzer-Ruppitsch; Petra Cejka; Jedrzej Kosiuk; Josef Neumüller; Marlene Almeder; Otto Majdic; Peter Steinberger; Udo M Losert; Johannes Stöckl; Leif Andersson; Johann Sölkner; Monika Vetterlein; Anna Golovko
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-08-28       Impact factor: 2.416

10.  Frequent p16-independent inactivation of p14ARF in human melanoma.

Authors:  Daniel E Freedberg; Sushila H Rigas; Julie Russak; Weiming Gai; Margarita Kaplow; Iman Osman; Faye Turner; Juliette A Randerson-Moor; Alan Houghton; Klaus Busam; D Timothy Bishop; Boris C Bastian; Julia A Newton-Bishop; David Polsky
Journal:  J Natl Cancer Inst       Date:  2008-05-27       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.